|
|
Blood, 15 March 2007, Vol. 109, No. 6, pp. 2565-2570.
Prepublished online as a Blood First Edition Paper on November 16, 2006; DOI 10.1182/blood-2006-06-032664.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Hypoxia-inducible transcription factor1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib
Lorenzo Veschini1,
Daniela Belloni1,
Chiara Foglieni2,
Maria Giulia Cangi3,
Marina Ferrarini1,
Federico Caligaris-Cappio1,4, and
Elisabetta Ferrero1
1 Laboratory of Tumor Immunology and Department of Oncology,
2 Department of Cardiology, and
3 Department of Pathology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) H San Raffaele, Milan, Italy;
4 Vita-Salute San Raffaele University School of Medicine, Milan, Italy
Angiogenesis is a complex, orchestrated process that plays a critical role in several conditions and has special relevance in the progression of cancer. Hypoxia is the major stimulus for angiogenesis, and hypoxia-inducible transcription factor1 alpha (HIF-1 ) is its key mediator. We set up a novel in vitro model of HIF-1 up-regulation by treating human umbilical vein endothelial cells (HUVECs) with the hypoxia-mimicking deferoxamine (DFO) and found that this condition was sufficient to promote angiogenesis, like the well-known HUVEC model cultured under low pO2. The proteasome inhibitor bortezomib, which induces strong apoptosis in cancer cells, abrogated proliferation and angiogenesis of HUVECs when used at a high concentration (100 nM), yet promoted both functions at a low dosage (10 nM). This double-edged effect appeared to be mediated by differential effects exerted by the different concentrations of bortezomib on 2 master regulators of tumor-associated angiogenesis, HIF-1 and nuclear factor kappa B (NF-kB). Significantly, when HUVECs were induced to express HIF-1 prior to bortezomib treatment, proliferative and angiogenic responses were abolished, and a greatly enhanced proapoptotic effect was promoted with both concentrations of the drug. These findings indicate that HIF-1 up-regulation may sensitize endothelial cells to the antiangiogenic and proapoptotic effects of bortezomib and might be exploited to target tumor-associated vessels in the course of antiangiogenic therapies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ann. Onc.,
March 1, 2009;
20(3):
413 - 424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Lin, M. Bazzaro, M.-C. Wang, K. C. Chan, S. Peng, and R. B.S. Roden
Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment
Clin. Cancer Res.,
January 15, 2009;
15(2):
570 - 577.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Fels, J. Ye, A. T. Segan, S. J. Kridel, M. Spiotto, M. Olson, A. C. Koong, and C. Koumenis
Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways
Cancer Res.,
November 15, 2008;
68(22):
9323 - 9330.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|